Transaction
|
December 14, 2021

Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors

Have a lightbulb moment with us
Sign up for updates from Tungsten
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.